United States-based Merck has received approval from the US Food and Drug Administration (FDA) for its human papillomavirus 9-valent vaccine, Gardasil 9, to be utilised as treatment for women and men aged from 27 years to 45 years, it was reported yesterday.
The company's supplemental application has been approved to expand the use of Gardasil 9, which helps in preventing certain cancers and diseases caused by the nine HPV types covered by the vaccine.
According to the Center for Disease Control and Prevention (CDC), around 14 million Americans are affected with human papillomavirus each year, and human papillomavirus viruses are associated with several other forms of cancer affecting men and women. Gardasil 9 had already received approval for use in males and females aged between nine years and 26 years.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval